Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2017 1
2019 2
2020 2
2021 5
2022 8
2023 3
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Procopio G, Claps M, Pircher C, Porcu L, Sepe P, Guadalupi V, De Giorgi U, Bimbatti D, Nolè F, Carrozza F, Buti S, Iacovelli R, Ciccarese C, Masini C, Baldessari C, Doni L, Cusmai A, Gernone A, Scagliarini S, Pignata S, de Braud F, Verzoni E. Procopio G, et al. Among authors: doni l. Tumori. 2023 Feb;109(1):129-137. doi: 10.1177/03008916221138881. Epub 2022 Nov 29. Tumori. 2023. PMID: 36447337 Free PMC article. Clinical Trial.
Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?
Rossi E, Bersanelli M, Gelibter AJ, Borsellino N, Caserta C, Doni L, Maruzzo M, Mosca A, Pisano C, Verzoni E, Zucali PA. Rossi E, et al. Among authors: doni l. Curr Oncol Rep. 2021 Nov 8;23(12):147. doi: 10.1007/s11912-021-01140-9. Curr Oncol Rep. 2021. PMID: 34748099 Free PMC article. Review.
Occurrence of Dysgeusia in Patients Being Treated for Cancer.
Di Meglio J, Dinu M, Doni L, Rossi G, Giorgione R, Colombini B, Antonuzzo L, Sofi F. Di Meglio J, et al. Among authors: doni l. Nutr Cancer. 2022;74(8):2868-2874. doi: 10.1080/01635581.2022.2042569. Epub 2022 Feb 23. Nutr Cancer. 2022. PMID: 35196919
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma.
Catalano M, De Giorgi U, Maruzzo M, Bimbatti D, Buti S, Mazzaschi G, Procopio G, Santoni M, Galli L, Conca R, Doni L, Antonuzzo L, Roviello G. Catalano M, et al. Among authors: doni l. Biomedicines. 2022 Sep 30;10(10):2444. doi: 10.3390/biomedicines10102444. Biomedicines. 2022. PMID: 36289706 Free PMC article.
25 results